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Background: Contrast induced nephrotoxicity (CIN) is a well described syndrome in humans undergoing contrast
medium examinations. To date CIN has received minimal attention in the veterinary literature despite increasing
use of contrast medium examinations in computed tomographic studies.
Methods: This prospective study evaluated the effect of 1290 mg/kg iohexol given intravenously to 5 normal
beagle dogs in a divided dose at an interval of 6–8 weeks. Renal function was evaluated by means of
scintigraphically determined glomerular filtration rate (GFR) and a variety of laboratory assays.
Results: Only GFR showed a significant decrease (17%) after the second injection but not to a clinically or
pathologically significant level.
Conclusions: No clinically significant effect of repeated contrast medium administration was determined in this
limited study. However in dogs with reduced renal function the risk of CIN is likely to increase dramatically post
contrast administration.
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Radiographic imaging using intravascular iodinated con-
trast agents was the mainstay of many advanced diag-
nostic procedures prior to the 1990s. The advent of
diagnostic ultrasound resulted in a marked decrease of
abdominal and cardiac contrast procedures in many re-
ferral institutions in the ensuing years. Since the turn of
the century there has been an increased use of com-
puted tomography (CT) which is currently a popular
diagnostic modality in veterinary science due to increas-
ing accessibility, enhanced applications and its minimal
invasiveness. Many of these CT studies included intra-
vascular contrast medium administration. Computed
tomography angiography (CTA), the study of vascular
structures by utilizing contrast agents during the CT
examination and multi-phase angiography to investigate
arterial and venous phases, as well as organ perfusion* Correspondence: robert.kirberger@up.ac.za.
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reproduction in any medium, provided the orhave seen a marked increase in veterinary use over the
last few years particularly with the advent of helical mul-
tislice CT machines. As the diagnostic advantages of
these techniques are being researched [1-7] increased
knowledge has lead to a dramatic increase in the use of
intravascular iodinated contrast agents again, and their
potential side effects must not be forgotten in routine
clinical practice.
The iodinated contrast agents used in diagnostic im-
aging are categorized according to their physical and
chemical properties [8]. First generation agents are all
high-osmolar ionic monomers [8]. Their high osmolality
results in increased rates of adverse reactions and they
have been replaced by the safer second and third gener-
ation agents. The most commonly used second generation
iodinated compounds (iopamidol and iohexol) are low
osmolar, non-ionic monomers which have improved vas-
cular tolerability and thus have fewer side effects [8]. As
the radio-opacity of a contrast medium is directly related
to the iodine content, the goal in developing successive
generations of contrast media has been to maximize theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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resulting solution. Third generation iodinated contrast
media (iodixanol and iotrolan) are iso-osmolar, non-ionic
dimers and are reported to be the safest contrast agents to
date. However, their high cost limits their use in human
patients at risk of contrast-induced nephrotoxicity (CIN)
[9,10] and in particular those patients with severe renal in-
sufficiency [11]. In contrast, other reports show no differ-
ence between second and third generation contrast agents
to induce CIN [12].
Adverse reactions to iodinated intravenous contrast
media have been extensively reported and investigated in
humans [8,12-15]. The side effects are related to their
physical and chemical properties. Side effects have been
classified as non-anaphylactoid, anaphylactoid and
delayed [8]. The non-anaphylactoid reactions include
pulmonary edema, cardiac arrhythmias, nausea, seizures
and renal failure. Anaphylactoid reactions can cause ur-
ticaria, laryngeal edema and bronchospasm. This is not a
true anaphylaxis as it is not stimulated by an immuno-
globulin E-mediated response and may also occur during
the first exposure to the agent [8]. However, treatment is
the same as for an anaphylactic reaction. The above
reactions appear within 1–3 minutes whereas delayed
reactions may occur up to 6 hours after exposure and
include fever, pruritis, arthralgia, headache, nausea and
vomiting and CIN [8].
Despite the incidence of CIN in the human population
being low (<2%), regardless of the contrast medium
used, [10] it is one of the leading complications of con-
trast use in human medicine and accounts for 10–11%
of all causes of hospital acquired renal failure [14,16].
Contrast induced nephrotoxicity manifests as an abrupt
decline in renal function as early as 24 hours and as long
as 7–10 days following contrast administration in the
absence of an alternative etiology. The patients usually
remain asymptomatic. In humans, CIN is characterized
by an increase in serum creatinine level of at least
44.2 μmol/L or 25% from baseline. In most cases this
rise has been reported to occur 24–72 hours following
exposure [8,9,12,13,16-18]. One publication cited that
the creatinine levels peaked at 96 hours post contrast ad-
ministration and thus CIN may be overlooked or underes-
timated in studies measuring creatinine concentrations at
48 hours or less [19]. Fortunately, CIN is usually self limit-
ing with serum creatinine levels returning to near baseline
values within 1–3 weeks [17]. Creatinine levels, although
most commonly used, are not the ideal method of evaluat-
ing CIN as renal function must be severely compromised
before elevation occurs [13]. Various risk factors for CIN,
such as pre-existing renal impairment, dehydration, dia-
betes mellitus (independently or with associated renal dis-
ease) and advanced congestive heart failure have been
identified [8,10,16,17,20,21] and thus, contrast agents maybe contributory rather than causative in CIN. Co-
morbidities such as hypertension, anaemia and peripheral
vascular disease may also play a role [20]. Arterial injec-
tions carry a slightly higher risk of developing CIN [8] and
there are conflicting reports on the effect of higher con-
trast agent dosages on the development of CIN [18,21].
However, in patients at risk, higher volumes are associated
with higher rates of CIN [16]. A recent report concluded
that human patients receiving repeat contrast CT exami-
nations within 24 hours, had a 12.4% incidence of CIN
and that an increase in the serum creatinine values be-
tween the first and second CT examination was highly
associated with CIN [22].
The mechanisms of CIN have been investigated during
numerous in vitro and in vivo studies. Multiple complex
factors result in hypoxia of the medulla and subsequent
acute tubular necrosis [16]. Three main mechanisms,
namely oxidative stress, hemodynamic disturbances
(vasoconstriction) and hyperosmolar effects are impli-
cated [9,12,13]. Low oxygen tension normally exists in
the renal medulla and this region of the kidney has a
high metabolic rate and oxygen requirement due to ac-
tive salt reabsorption in the medullary thick ascending
limbs of the loops of Henle [16,20]. Contrast agents ag-
gravate this outer medullary hypoxia as they cause
enhanced metabolic activity and oxygen consumption as
a result of osmotic diuresis [13]. As contrast media may
be uricosuric and may increase the excretion of both ox-
alate and Tamm-Horsfall proteins, there is a theory that
contrast nephrotoxicity may be mediated by tubular ob-
struction [13]. Pathological studies of animal models of
CIN often reveal vacuolation of the proximal tubular
epithelium [21]. Recent studies have also implicated a
decrease in the antioxidant enzyme activity and/or an in-
crease in oxygen free radicals as a putative mechanism
for CIN [13]. During an in vitro study of the effect of
contrast agents on various cell lines, the cytotoxic effect
of the contrast agent causing renal cell apoptosis was
identified as early as 15 minutes of incubation, reaching
a maximum at 3 hours [14]. Several studies have docu-
mented a contrast induced rise in various proteins and
enzymes, which although non-specific for tubular dam-
age, do support a theory of a direct toxic effect on the
tubular epithelium [21]. Studies into the pathogenesis of
CIN have focused on the ischemic effects on the renal
cells. It has been repeatedly demonstrated that when
contrast medium is injected directly into the renal artery
of both dogs and humans, there is a biphasic response
in the blood flow. There is an initial very brief increase
in flow, followed by a period of reduced flow lasting sev-
eral minutes in normal kidneys. This reduced flow is
most likely due to intrarenal vasoconstriction. Elevations
of adenosine and endothelin are the main contributors
to this vasoconstriction [16,20]. This vasoconstriction is
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the increased production and decreased removal of free
oxygen radicals, which correlates directly with a decrease
in the glomerular filtration rate (GFR) [21].
In humans CIN may be limited by reducing the
amount of contrast used and using fluid therapy for 3–
24 hours before and 6–24 hours after the procedure
[13,17,20,23]. Use of 0.9% saline at 1–3 ml/kg/hour be-
fore and 1 ml/kg/hour after the procedure is advised
[20]. In some studies the addition of sodium bicarbonate
appears to have had a beneficial effect [24]. The use of
diuretics is generally contraindicated [17]. This creates a
conundrum as diuretics are used in human excretory ur-
ography CT [25] as well as in dogs at our institution for
the evaluation of ectopic ureters. These dogs may well
have subclinical renal involvement and would thus be
more susceptible to CIN. Vasodilating and antioxidant
pharmacologic agents that have been used with varying
success to limit CIN, include prostaglandins, dopamine,
adenosine antagonists such as theophyline, and antioxi-
dants, particularly N-acetylcystine, to name but a few
[13,14,20,23,24,26].
There is a paucity of literature on adverse contrast
agent effects in animals and in particular CIN. A recent
CT textbook only mentions CIN in passing [6]. Three
decades ago, a study was done to determine the effect of
three increasing dosages excretory urograms at 48 hour
intervals on GFR in dogs as determined by blood urea
nitrogen (serum urea), serum creatinine and endogenous
creatinine clearance [27]. The contrast agent used was
sodium iothalamate, a first generation contrast agent.
Only the endogenous creatinine clearance decreased in
50% of the dogs, indicating some decrease in GFR fol-
lowing contrast urography. Acute renal failure is
described in a 14-month-old dog 190 hours after excre-
tory urography with a first generation contrast agent.
The dog recovered after four days of intensive treatment
[28]. Only one experimental study to date has looked at
CIN in control and gentamycin induced renal dysfunc-
tion in dogs and the effect of a low dose of dopamine
and 0.9% saline to reduce potential CIN and improve ex-
cretory urography image quality [29]. Serum chemistry
assays included serum urea and creatinine. This study
showed increased serum urea levels 72 hours after injec-
tion of contrast medium only in dogs with normal renal
function. Interestingly dogs with impaired renal function
showed no significant change in serum urea values.
More work has been done on anaphylactoid reactions.
A severe reaction in 2 anesthetized dogs undergoing CT
angiography with first generation ionic intravenous con-
trast media has been described [30]. One dog developed
hypertension, bradycardia, apparent bronchospasm and
diarrhea and the other became hypotensive, tachycardic
and had ventral abdominal and pelvic limb erythemaand diarrhea. Both dogs recovered after intensive treat-
ment. Recent retrospective studies reported on the effect
of first and second generation contrast media CT studies
in dogs and cats on heart rate, peak systolic blood pres-
sure and serum urea and creatinine concentrations
[31,32]. There were minor hemodynamic changes with
some serum biochemistry changes which were difficult
to interpret due to low numbers and varying histories
and sampling intervals. The serum urea and creatinine
post injection time measurements were often weeks to
months later and thus were of no value to determine
possible CIN within 24–96 hours post injection. One
equine report using intravenous contrast medium in an
18-year-old Dutch warm blood could be found. The
horse received a total dose of 480 ml of first generation
contrast agent for a head CT. The horse developed a se-
vere anaphylactoid reaction (bronchospasm, hypoxemia,
hypotension and sweating), but recovered after intensive
monitoring and treatment [33]. More recently a report
on the effects of distal extremity limited volume intra-
arterial contrast medium administration in horses
showed 4% developing anaphylactoid reactions (urticaria
and edema) whilst 5% developed a temporary increase in
heart rate and blood pressure [34].
Glomerular filtration rate is a good measure of renal
function as it is directly proportional to the number of
functioning nephrons [31]. It is considered to be the best
parameter to estimate renal function for diagnosis and
prognosis in clinical situations [35]. Glomerular filtration
rate cannot be measured directly but is estimated using
the uptake or clearance of a filtration marker. Filtration
markers for GFR must satisfy several physiologic require-
ments which include: 1) being freely filtered by the glom-
eruli, 2) not being bound to plasma protein and 3) not
being reabsorbed, secreted or metabolized by the renal
tubules [36-38]. Many methods have been developed and
described, including endogenous and exogenous creatin-
ine clearance, C-inulin clearance, iodinated contrast
medium clearance, contrast enhanced renal CT and
99mTc-diethylenetriamine pentacetic acid (99mTc-DTPA)
scintigraphy [36,37,39]. The traditional gold standard for
measuring GFR is the determination of exogenous inulin
clearance; however this method is technically difficult as it
requires timed collection of both urine and plasma
[36,38]. The scintigraphic GFR technique is quick and
non-invasive, does not require blood or urine samples and
can also asses individual kidney GFR [36,39,40]. However
it requires expensive equipment, an authorized laboratory
and technical expertise. Although global and regional GFR
can be measured using contrast enhanced CT, the results
in a canine study revealed lower CT GFR values when
compared to scintigraphy [37]. It was hypothesized that
the difference may have been as result of the anesthetic
effects during the CT on blood pressure, cardiac output
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toxic effects of the iohexol.
The scintigraphic method can be more variable than
the plasma clearance methods, due to the short imaging
time, environmental factors affecting GFR and inter-
operator variability [35,36,40-42]. The dynamic renal
scintigram is based on 2 minute sampling time during
which auto regulatory mechanisms may alter renal blood
flow and pressure [36]. Day-to-day variability’s include
gamma camera variations, stress (dogs should be accli-
matized to the scintigraphic procedure), hydration sta-
tus, water and food intake and composition, particularly
protein content. The amount of protein binding of the
radiopharmaceutical is also an important factor to con-
sider as the radiopharmaceuticals bound to protein is
not available for GFR and will result in a false lower
GFR value. The amount of protein binding of 99mTc-
DTPA is said to be low in dogs and cats (10–15%) and
does not significantly influence the GFR [36,40]. Interob-
server variability of GFR can be overcome by using
semi-automated methods to determine the region of
interest (ROI) and by averaging three measurements
made by one observer [35]. All of the above result in
some degree of variation of results in normal kidneys. In
animals with compromised renal function the values will
be more consistent as the kidneys are operating at or
near their maximum GFR [36]. Normal values in the
dog are generally above 3 ml/min/kg and vary from
3.13 ± 0.53 to 3.97 ± 0.72 and 4.05 ± 1.1 ml/min/kg
[36,37,41,43] Subclinical renal insufficiency has GFR
values between 1.2 and 2.5 ml/min/kg. Animals with
levels below 1–1.3 ml/min/kg often have elevated serum
urea and creatinine concentrations [36].
Various serum chemistry assay and urinalysis findings
are evaluated when a suspicion of acute renal damage
exists. Serum creatinine and serum urea concentrations
provide an estimation of GFR but have poor sensitivity in
that they do not become elevated until there is significant
renal insufficiency [36,38,39]. Azotemia may also be influ-
enced by extraneous factors. Serum inorganic phosphorus
(SIP) can be maintained within relatively normal limits for
some time by the endocrine responses involved in renal
secondary hyperparathyroidism. Similar to serum creatin-
ine and serum urea concentrations, SIP shows poor sensi-
tivity as it is thought that approximately 85% of the GFR
must be lost before persistent hyperphosphatemia devel-
ops [44]. Urinalysis findings, such as glucosuria and pro-
teinuria, can also alert one to renal damage. In various
studies in dogs with gentamycin induced nephrotoxicity,
24 hour urinary gamma-glutamyl transpeptidase (GGT)
and spot urine sample GGT:creatinine ratio were found to
be more sensitive and reliable methods of detecting tubu-
lar damage, particularly in the early phase, before other
serum and urine findings where altered [45,46]. Urineprotein:creatinine (UPC) ratio is useful to quantify urin-
ary protein loss from renal origin [47]. However in dogs
with stable proteinuria UPC values in the lower ranges
may differ as much as 40% limiting its value in transient
nephropathy [47].
The objective of this study was to determine the effect
on renal function of two standard dosages of intravenous
iohexol 6–8 weeks apart in normal dogs by using scinti-
graphically determined GFR and a variety of laboratory
assays. The study ran concurrently with a CTA study
that will be reported elsewhere. The hypotheses posed
were: GFR will decrease, serum urea, creatinine, and SIP
concentrations as well as urine GGT:creatinine and UPC
ratios will increase after the two CTA procedures. The
authors acknowledge that 5 dogs are a small sample
population and that the expected minor changes in renal
function induced by the contrast agent would require a
larger number of dogs to give the study the required
statistical power in some of the tests. However, as a trial
was already being undertaken by the authors to compare
different CTA techniques in 5 dogs, it provided an ideal
opportunity to do a preliminary prospective investigation
on the effects of contrast media on renal function, and
in particular GFR, which is much more sensitive than
routine laboratory evaluations of renal function.
The protocol was approved by the University of Pre-
toria animal use and care committee as well as research
committee (Protocol number V044-09).
Materials
Subject material
Five normal adult purpose bred laboratory Beagles,
three males and two females, all but one male and one
female sterilized, were used. Dogs had a mean age of
48± 15 months (range 37–68) and weight of 13.81 ± 2.4 kg
(range 10.4–16.1). The dogs were determined to be
healthy 4 days before the onset of the trial based on
normal clinical examination, thoracic radiographs, ab-
dominal ultrasound, blood pressure (non-invasive oscil-
lometric technique) and a complete blood count. Renal
function normality was assessed as reported below. The
dogs were housed in the Onderstepoort Veterinary Aca-
demic Hospital during each of the 7 day study periods
and were fed a commercial diet twice daily and given
water ad libitum. The animals were fasted for 12 hours
preceding the GFR and CTA studies and water was pro-
vided ad libitum up to sedation. In between the study
periods the dogs were housed at the University of Pre-
toria Biomedical Research Centre or the Onderstepoort
Teaching Academic Unit.
Clinical pathology
Routine urine analysis as well urine GGT, protein and
creatinine values were determined. From the latter GGT:
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serum biochemistry panel (serum urea, creatinine, SIP,
sodium and potassium) was performed on all the dogs
as part of the initial screening, 72 hours prior to,
72 hours and 2 weeks after each CTA. Albumin and
globulin concentrations were obtained as part of the ini-
tial screening and again 72 hours before and 72 hours
after the second contrast medium injection.
Iohexol administration
All dogs were part of a separate thoracic CTA trial com-
paring bolus tracking and test bolus techniques. Each
dog received each CT technique 6–8 weeks apart start-
ing with bolus tracking with each dog receiving 2 ml/kg
iohexol (300 mgI/ml – total dose 600 mg/kg) (Omnipa-
que, Adcock Ingram Healthcare, Bryanston South Af-
rica) administered with a pressure injector at 3 ml/sec.
Test bolus dogs received a manually injected test bolus
of iohexol 300 mgI/ml (15% or 0.3 ml/kg of the total
dose of 2 ml/kg) followed by an additional dose of 2 ml/
kg administered with a pressure injector at 3 ml/sec. All
injections, including the test bolus, were followed by a
manual saline chaser of 1 ml/kg. The total dose received
for the test bolus technique was thus 690 mg/kg and the
combined trial dose for each dog was 1290 mg/kg.
Scintigraphic GFR
The scintigraphic GFR was performed on all the dogs
72 hours prior to, and 72 hours after each CTA.
The anesthetic protocol was adapted from previous
studies to minimize the effects of drugs on the GFR
[42,43]. Dogs were premedicated with intravenous
butorphanol (TorbugesicW, Pfizer laboratories, Sandton,
South Africa) at 0.4 mg/kg and diazepam (Aspen Phar-
macare, Woodmead, South Africa) at 0.2 mg/kg. This
combination has minimal effect on blood pressure so as
to reduce the risk of aggravating a potential CIN. Induc-
tion followed 5 minutes later with intravenous propofol
(Fresenius Kabi, Midrand, South Africa) to an effective
level of deep sedation. Additional doses of propofol were
given if required to keep the dog motionless. Propofol
was added to the regimen as it has been shown that
butorphanol and valium on their own may not result in
sufficient sedation in young healthy dogs [43]. A gamma
camera (Equine scanner HR, Medical Imaging Electron-
ics, Burkhard Rauchfub. Haupt str. 112. 23845 Seth,
Germany) fitted with a Low Energy All Purpose (LEAP)
collimator and a 64 by 64 x 16 matrix was used.
The GFR studies were done in a similar manner to previ-
ously described techniques [35,38,41], and at the same time
of the day within a 2 hour window between 10 and 12 pm.
Commercially supplied 99mTc-DTPA (Syncor 917 Morkels
close, Unit F81, Allandale Park, Midrand, South Africa) was
administered as a 1 ml bolus with the dose calculated bysubtracting the dose remaining in the syringe after injection
from the full syringe dose. As all counts were made within
10 minutes of injection, radioactive decay measurements
were deemed unnecessary [39,48]. Mean dose administered
was 142±21.4 MBq (range 97.2–172.1). The patient was
positioned in left lateral recumbency with the gamma cam-
era positioned dorsal to the kidneys. The 99mTc-DTPA was
manually injected into the cephalic vein followed by a 1 ml/
kg saline flush. Image acquisition was initiated simultan-
eously with injection. Images were acquired at 6 second
intervals for 3 minutes. After the dynamic acquisition the
camera was rotated 90 degrees and a 30 second right lateral
static image was made for renal depth correction calcula-
tions. Images were displayed sequentially and corrected for
motion when necessary using motion correction software.
Composite images of the dynamic series were used to form
a single image of the kidneys with sufficient counts to de-
fine the renal edges. A manual renal ROI was drawn allow-
ing up to 1–2 pixels peripheral to the high intensity uptake
to be included. Background (1–2 pixels cranial and caudal
to each kidney) rectangular 3×7 pixel regions of interest
were drawn avoiding other isotope uptake areas. A time ac-
tivity curve was created by applying the regions of interest
to the dynamic data from 1 to 3 minutes to avoid pelvic iso-
tope uptake hampering interpretation after 3 minutes
[39,48]. Depth correction was used to determine individual
renal function to the total renal function by the computer.
To reduce observer variability all measurements were made
by one investigator (NC) and repeated three times and a
mean value obtained. All dogs were kept in isolation for
24 hours following the scintigraphy.
Data and statistical analysis
Data were captured on a spreadsheet and statistically
analyzed using the SPSS 17.0 statistics package (IBM
Southern & Central Africa, Private Bag x9907, Sandton,
South Africa). Results were expressed as mean +/−
standard deviation (SD) and range. Statistical tests were
performed between the 6 times the dogs were evaluated
for all the tests except for the GFR which only had 4 test
times. Because of the low number of dogs tested, non-
parametric tests were run, namely Friedman’s ANOVA
and if there was a significant difference Wilcoxon’s
signed rank test were performed on these data to deter-
mine whether there was significant difference between
the means at different testing times. The significance
level for all tests was set as P < 0.05. Power analysis done
for the GFR, which had very low standard deviations
revealed the number of dogs tested to be sufficient.
Results
Clinical pathological values
Albumin, globulin, sodium and potassium values
remained within normal limits throughout the study.
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normal limits of 40–133 μmol/L with a range of 55–
107 μmol/L. There was no significant difference among
the combined data (P = 0.053). There was a significant
increase of serum creatinine concentration values from
72 hours before the first CTA to 72 hours before the
second CTA (73.8 vs 82.6 μmol/L, respectively;
P = 0.031), and a significant decrease between the
72 hours before the second CTA and 72 hours after the
second CTA (82.6 vs 68 μmol/L, respectively; P = 0.031)
(Figure 1).
The serum urea values remained within the normal
limits of 3.6–8.90 mmol/L except for one dog with a
value of 9.4 mmol/L, 72 hours after the second CTA.
One pre first CTA sample could not be evaluated for
technical reasons. The highest mean value for the test
periods was 6.36 mmol/L 72 hours before the second
CTA compared to an initial value of 5.7 mmol/L. There
was no statistically significant difference between the
various groups’ combined data (P = 0.742).
The SIP values remained within normal limits of 0.90–
1.60 mmol/L except for 4 random values of which 3
were above and 1 below normal. There was no statisti-
cally significant difference between the various groups’
combined data (P = 0.195), but there was a significant in-
crease between the 2 weeks post first CTA and 2 weeks
post second CTA (1.24 vs 1.59 mmol/L, respectively;
P = 0.031), and between the 72 hours pre second CTA
and 2 weeks post second CTA (1.38 vs 1.59 mmol/l, re-
spectively; P = 0.031) (Figure 2).
Urine creatinine concentrations were not determined
in 2 pre first CTA samples due to technical reasons. The
urinary GGT:creatinine remained fairly constant with a
mean of 0.20 for the whole study and a minimum meanFigure 1 Graph showing serum creatinine values in μmol/L pre- and p
time intervals. Reference values for our laboratory are 40–133 mmol/L.of 0.18 and maximum mean 0.23 during each test
period. All these values were well below the reported
normal value of 0.39 ± 0.18 [46]. There was no statisti-
cally significant difference between the various groups’
combined data (P = 0.198). The UPC ratios also
remained well within normal limits of <0.5 [49] with the
mean value for each test period being 0.11 (range 0.08-
0.13). There was a trend for the values to increase
2 weeks after the first injection and 3 days after the sec-
ond injection, but this was not significant.
The 99mTc-DTPA GFR scintigraphy showed a signifi-
cant difference between the combined groups’ values
(P = 0.016), with the mean GFR value 72 hours prior to
first CTA of 3.284 increasing significantly to 3.54 ml/
min/kg 72 hours after the first CTA procedure
(P = 0.031) and then dropping significantly from 72 hours
before the second CTA from 3.578 to 2.962 ml/min/kg
72 hours after the second CTA (P = 0.031) (Figure 3).
Discussion
There was no significant difference between the various
groups’ combined data for the urine and serum bio-
chemistry panel changes and the only significant changes
between individual data groups over the period of the
trial were serum creatinine and SIP concentrations. The
3 samples that could not be evaluated for technical rea-
sons were all pre-first CTA procedure and hence could
not really affect the outcome of the rest of the sample
analyses. The UPC ratio was the only urine test that
showed an increasing trend. Serum creatinine concen-
trations showed a significant increase between 72 hours
before the first CTA and 72 hours before the second
CTA which was an interval of 6–8 weeks with no signifi-
cant changes 72 hours after each injection as expected.ost injection of contrast medium 6–8 weeks apart. See text for
Figure 2 Graph showing serum inorganic phosphate values in mmol/L pre- and post injection of contrast medium 6–8 weeks apart.
See text for time intervals. Reference values for our laboratory are 0.90–1.60 mmol/L.
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and was an increase of 8.8 μmol/L (12%). Compared to
human studies this increase is not clinically significant
as CIN is characterized by an increase in serum creatin-
ine concentration of at least 44.2 μmol/L or 25% from
baseline [12,17,18]. An additional confounder was the
significant decrease in concentrations between 72 hours
before and 72 hours after the second contrast injection
(82.6 vs. 68 μmol/L, respectively) when most human
studies show an increase 24–72 hours following expos-
ure [8,9,12,13,16-18]. Creatinine concentrations have
been reported to peak up to 96 hours post contrast ad-
ministration and a possible elevation may theoretically
have been missed [19]. Fortunately CIN is usually selfFigure 3 Graph showing GFR values in ml/min/kg 72 hours pre- and
reported values are greater than 3.13 ± 0.53 ml/min/Kg.limiting and if an elevation occurred this usually returns
to near baseline values within 1–3 weeks [17] making
the 6 weeks later elevation also unlikely to be clinically
significant.
The serum urea concentrations showed no significant
increase confirming the insensitivity of this test to detect
early renal dysfunction [35,38,39].
The SIP concentrations also showed some significant
increases but not beyond normal levels and not in the
expected time intervals of 72 hours post injection, again
making these findings unlikely to be clinically significant.
The GFR increased by 0.26 ml/kg/hour from 3.284 to
3.54 ml/kg/hour, 72 hours after the first injection. This
increase was unexpected and was statistically significantpost injection of contrast medium 6–8 weeks apart. Normal
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tions may be due to several causes. These include day-
to-day variability and technical errors [41] or can be
attributed to renal physiologic homeostatic adjustments
[50]. Additionally, scintigraphically determined GFR is
based on a 2 minute sample and GFR can vary consider-
ably over short time intervals due to autoregulation [50].
The only possible clinically significant value of the whole
trial was the decrease of GFR by 0.6 ml/kg/hour from
3.56 to 2.96 ml/kg/hour from 72 hours before to
72 hours after the second injection. This is below the
normal values quoted in most studies [36,37,41] but
within one standard deviation of the lowest reported
normal value [43].
However the decrease in GFR should alert clinicians
to the potential of CIN. It is suggested that all patients
undergoing CT angiography should at least have their
serum urea and creatinine concentrations, and if avail-
able UPC ratios, checked prior to the procedure. Based
on human studies, dogs with elevated values believed to
be of renal origin as well as diabetic dogs are likely to be
at risk. These patients should be placed on an intraven-
ous Ringer’s infusion at 1–3 ml/kg/hour for at least 3–
6 hours before the angiography and 1 ml/kg/hour for
3 hours afterwards. Normal dogs should also be placed
on maintenance fluids for at least 2 hours before and
after the procedure. Additionally, epinephrine and intra-
venous prednisolone sodium succinate must be on hand
to treat anaphylactoid reactions.
The effect of propofol on cardiorespiratory parameters
is contradictory in the literature. One report commented
that no clinically significant changes in blood pressures
or heart rates were observed when propofol was used in
combination with diazepam [51]. In another study inves-
tigating the anesthetic cardiopulmonary effects of propo-
fol in dogs premedicated with butorphanol, atropine and
medetomidine, a transient decrease in blood pressure
was noted after propofol injection [52]. However in sed-
ation related systemic hypotension GFR is usually main-
tained at normal levels by maintenance of renal blood
flow [43]. So although the effects of the balanced
anesthesia used in the study would require further inves-
tigation to further define the effects on blood pressure
and subsequently GFR, each dog served as its own con-
trol and the same anesthetic protocol was used during
each scintigraphic examination. Thus a trend in the GFR
would still be identified. The only concern regarding any
potential effects on the use of propofol would be in a pa-
tient with subclinical renal insufficiency as a decrease in
blood pressure may exacerbate the condition.
The limitations of this study are the small number of
dogs with only 4 GFR studies done on each dog. How-
ever, even when power analyses were conducted on the
GFR results of the 5 dogs, the results were such that thenumber of dogs were deemed to be sufficient. It may
have been that CIN was present after injection of con-
trast medium but that it occurred later than the 72 hour
GFR determination but additional 96 hours post injec-
tion GFR determinations was also not within the context
of the overall study. However the study did show that 2
doses of iohexol given 6–8 weeks apart did not have a
major influence on renal function in these 5 normal
dogs. The study was done on normal dogs and the
effects of contrast medium in dogs with impaired renal
function can only be speculated upon based on human
studies. To perform a similar GFR study in clinical case
material would be logistically challenging and to create
renal damage for an experimental study would be ethic-
ally questionable.
Conclusion
The null hypotheses of increased serum urea, creatinine
and SIP concentrations and increased urine GGT: cre-
atinine and UPC ratios after the two CTA procedures
could not be proven in this limited study. A 17% de-
crease in GFR was shown after the second contrast
medium injection. Whether this was a clinically signifi-
cant induction of CIN is difficult to confirm/conclude
taking into consideration the potential variations in
GFR. No GFR studies could be found in the human lit-
erature to detect changes in renal function in CIN cases
and all human research is based on elevated creatinine
values which are known to only increase when signifi-
cant renal change has occurred. The final mean GFR of
2.96 ml/kg/hour in this study is still not believed to be
clinically significant as subclinical renal insufficiency has
reported GFR values between 1.2 and 2.5 ml/min/kg
[36]. However the potential of CIN should be considered
in all patients undergoing contrast medium studies, par-
ticularly if reduced renal function is present, and appro-
priate preventative measures instituted.
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